For its analysis, KFF researchers measured the share of total Medicare Part D and Part B drug spending for top-selling prescriptions in 2019 that were covered by each part.
Four fast facts to know:
1. Sixty percent of net total Part D spending, or $87 billion, came from the 250 top-selling drugs in Medicare Part D.
2. The top 250 Part D drugs, which account for only 7 percent of all Part D covered drugs, had one manufacturer and no generic or biosimilar.
3. Eighty percent of Medicare Part B drug spending, or $30 billion, came from the top 50 drugs.
4. The top 50 Medicare Part B drugs only account for 8.5 percent of all Part B covered drugs.
Read the full analysis here.
More articles on payers:
Biden administration revokes billions in Texas Medicaid funding
UnitedHealth profit nears $5B in Q1
Avalere founder to head up JPMorgan healthcare innovation
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
